Focus on cannabinoids and synthetic cannabinoids

  title={Focus on cannabinoids and synthetic cannabinoids},
  author={R. Le Boisselier and J. Alexandre and V. Lelong-Boulouard and D. Debruyne},
  journal={Clinical Pharmacology & Therapeutics},
  • R. Le Boisselier, J. Alexandre, +1 author D. Debruyne
  • Published 2017
  • Medicine
  • Clinical Pharmacology & Therapeutics
  • The recent emergence of a multitude of synthetic cannabinoids (SCs) has generated a wealth of new information, suggesting the usefulness of state‐of‐the‐art on lato sensu cannabinoids. By modulating a plurality of neurotransmission pathways, the endocannabinoid system is involved in many physiological processes that are increasingly explored. SCs desired and adverse effects are considered to be more intense than those observed with cannabis smoking, which is partly explained by the full agonist… CONTINUE READING
    52 Citations

    Paper Mentions

    Cannabinoids as anticancer therapeutic agents
    • 3
    Synthetic cannabinoids: characteristics, use and clinical implications
    • 8
    • PDF
    Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy
    • 4
    • PDF
    Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products
    • 2
    • PDF
    Uses, Effects and Toxicity of Synthetic Cannabinoids from the Perspective of People with Lived Experiences
    Synthetic Cannabinoids and Cardiac Arrhythmia Risk: Review of the Literature
    • 5
    • Highly Influenced
    New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites
    • 14
    • PDF
    Pharmacodynamics of cannabinoids
    • 1
    • PDF
    Cannabinoids and the eye.


    Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
    • 368
    Emerging drugs of abuse: current perspectives on synthetic cannabinoids
    • 64
    • PDF
    Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.
    • 50
    Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities
    • R. Pertwee
    • Medicine
    • Philosophical Transactions of the Royal Society B: Biological Sciences
    • 2012
    • 241
    • PDF
    Cannabidiol, neuroprotection and neuropsychiatric disorders.
    • 124
    • PDF
    Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
    • 542
    • PDF
    A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids.
    • 62
    Medicinal chemistry of cannabinoids
    • 67
    • PDF
    Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives
    • 27